Repros Therapeutics Inc. Reports Findings From The Six Month Study Of Androxal® In Men With Secondary Hypogonadism
Published: Feb 10, 2014
THE WOODLANDS, Texas, Feb. 10, 2014 (GLOBE NEWSWIRE) -- Repros Therapeutics Inc.® (Nasdaq:RPRX)today reported additional results from its ZA-300 six month study of Androxal® in men with secondary hypogonadism. Literature suggests that secondary hypogonadism is strongly linked to obesity and a variety of maladies that accompany the metabolic syndrome. Some of these accompanying disorders include high cholesterol and poor glycemic control as many men affected by secondary hypogonadism either have or are candidates for cardiovascular disease and/or type 2 diabetes.
Help employers find you! Check out all the jobs and post your resume.